Clinical Trial Update: A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC [Phase 2]

View source ↗

Summary

This Phase 2 trial in EGFR-mutant, MET-amplified advanced non-small cell lung cancer compares Savolitinib plus Osimertinib versus Savolitinib plus placebo, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Savolitinib (savolitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-09-24